Phaseline

Companies › Vivet Therapeutics SAS

Vivet Therapeutics SAS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VTX-801
Replication-deficient recombinant adeno-associated viral vector (rAAV) with liver-tropic c
ATP7BPhase 1Wilson's DiseaseJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04537377VTX-801Phase 1Wilson's DiseaseMetabolic and endocrineJun 2029

Targets

ATP7B (1)

Companies with the same targets

Ultragenyx Pharmaceutical Orphalan Prime Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.